iShares Nasdaq Biotechnology ETF

Most Recent

  • uploads///Graph
    Earnings Report

    Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success

    On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

    By Margaret Patrick
  • uploads///Relative valuation
    Earnings Report

    Regeneron Continues to Trade at Premium

    Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio

    Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

    By Margaret Patrick
  • uploads///Eylea
    Earnings Report

    Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?

    Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

    By Jillian Dabney
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Celldex Rose on Phase 2 Melanoma Data

    On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Product Line Extension

    As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

    By Margaret Patrick
  • uploads///attractive product profile
    Company & Industry Overviews

    What’s behind Biogen Buyout Rumors?

    Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Amgen: Exploring Opportunities in the Bone Segment

    Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials

    Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

    By Peter Neil
  • uploads///Krystexxa
    Company & Industry Overviews

    Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio

    In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

    By Jillian Dabney
  • uploads///BioMarin Timeline
    Company & Industry Overviews

    Overview of BioMarin: History and Product Portfolio

    Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02

    Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.

    By Peter Neil
  • uploads///Kanuma
    Earnings Report

    How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings

    Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.

    By Jillian Dabney
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial

    On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

    By Peter Neil
  • uploads///Graph pipeline
    Company & Industry Overviews

    BMN 270: A Big Valuation Catalyst for BioMarin

    On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

    By Jillian Dabney
  • uploads///patents
    Company & Industry Overviews

    Why Is Enbrel So Important for Amgen?

    YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.

    By Jillian Dabney
  • uploads///gks
    Earnings Report

    How Has Aquinox Performed Compared to Peers?

    Aquinox has a positive future outlook and will likely continue to better its performance in the near future.

    By Gabriel Kane
  • uploads///SHPG
    Fund Managers

    Shire Gets Dropped from AQR Capital’s Portfolio

    During the fourth quarter of 2014, AQR Capital closed its position in Shire plc (SHPG). The fund sold its entire stake of 816,116 shares in the company.

    By Stuart McKenzie
  • uploads///nerve cell _
    Company & Industry Overviews

    Aptinyx Stock Plunged 70% after Clinical Trial Failure

    Today, Aptinyx (APTX) is trading at $5.26, which is a ~70.5% decline from yesterday’s closing price of $17.83.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Valuation Continues to Lag behind Peers

    Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Which of Amgen’s Drugs Could Witness Muted Growth in 2016?

    Wall Street analysts have projected that Xgeva’s revenues will reach about $1.6 billion in 2016, which represents a YoY growth of about 12.3% for Amgen.

    By Margaret Patrick
  • uploads///PE multiple
    Company & Industry Overviews

    Why Is Vertex Pharmaceuticals’ Valuation at a Discount?

    On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).

    By Jillian Dabney
  • uploads///Spectrum
    Company & Industry Overviews

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

    By Daniel Collins
  • uploads///ANR
    Earnings Report

    What Can Investors Expect from Regeneron’s 4Q15 Earnings?

    Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.

    By Jillian Dabney
  • uploads///microscope _
    Earnings Report

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.

    By Mike Benson
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///Sharpe Ratio Formula
    Healthcare

    Why you should use the Sharpe ratio when investing in the medical device industry

    What is a Sharpe ratio? A Sharpe ratio is a tool that measures the amount of returns for each unit of volatility that’s generated by a portfolio (higher returns and lower volatility equals more returns per unit of volatility). The measurement allows investors to analyze how much return they’re receiving from a portfolio in exchange for […]

    By Amritpal Khalsa
  • Financials

    Must-know: 2 stock market segments offering good value

    Equities in the more expensive market segments are particularly vulnerable.

    By Russ Koesterich, CFA
  • Financials

    Must-know: Are market valuations stretched?

    The NASDAQ Biotechnology Index (IBB) is up 14% this year—less than a third of its 122 companies earned any money in the last 12 months.

    By Russ Koesterich, CFA
  • uploads///AdobeStock_
    Consumer

    Where Did Stanley Druckenmiller Place His Bets?

    In the second quarter, Stanley Druckenmiller’s top five buys were Uber Technologies, Microsoft, Salesforce.com, PG&E, and Barrick Gold.

    By Rabindra Samanta
  • uploads///seedling _
    Company & Industry Overviews

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.

    By Mike Benson
  • uploads///capsule pill health medicine
    Company & Industry Overviews

    Celgene’s Financial Position before Its Third-Quarter Earnings

    Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.

    By Daniel Collins
  • uploads///marijuana _
    Healthcare

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    How Ionis’s Q2 2018 Earnings Trended

    Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Shire’s Q2 2018 Earnings on July 31

    Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.

    By Mike Benson
  • uploads///drug _
    Earnings Report

    Amgen Beats Estimates, Reports Growth in Q2 2018

    Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Amgen Announced the Phase 3 Results for ABP 710

    On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why Editas Medicine Fell 7.8% on Monday

    On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///dna _
    Healthcare

    Why Axovant Sciences Stock Jumped ~160% on Wednesday

    Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.

    By Mike Benson
  • uploads///ABMD PE MC
    Healthcare

    Analyzing ABMD, BR, and TFX Stocks

    Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively.

    By Amanda Lawrence
  • uploads///blood __
    Company & Industry Overviews

    No Bid Coming for Shire Reportedly

    Will Allergan buy Shire? – Apparently not CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier. From earlier: Shire PLC (NASDAQ: SHPG) is up 4.5% as of 11:10 A.M. on Thursday following an announcement […]

    By JP Gravitt
  • uploads///flag _
    Consumer

    Can You Avoid the Tariff Trouble in the S&P 500?

    Over the last couple of days, the market had given some reasons to be more positively inclined.

    By JP Gravitt
  • uploads///test
    Company & Industry Overviews

    Gilead Sciences’ Valuation in March 2018

    Gilead Sciences surpassed analysts’ estimates and reported an EPS of $1.78 on revenues of $5.9 billion during 4Q17.

    By Mike Benson
  • uploads///Spinraza
    Company & Industry Overviews

    How Biogen’s Spinraza Is Positioned for 2018

    In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.

    By Daniel Collins
  • uploads///ARRY
    Company & Industry Overviews

    Array BioPharma’s Promising Drug for Colorectal Cancer

    On January 22, 2018, Array BioPharma announced data from the BEACON CRC trial, which showed a median progression-survival rate of eight months and an overall response rate of 48%.

    By Kenneth Smith
  • uploads///Elacestrant market opportunity
    Company & Industry Overviews

    Taking Stock of Radius Health’s Licensing Agreements

    The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.

    By Kenneth Smith
  • uploads///ARWR Drug Pipeline
    Company & Industry Overviews

    Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

    Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.

    By Kenneth Smith
  • uploads///Celgene acquires
    Company & Industry Overviews

    Celgene to Acquire Juno Therapeutics

    On January 22, 2018, Celgene and Juno Therapeutics announced a merger agreement in which the former will acquire the latter’s business.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline

    On January 10, 2018, Vertex Pharmaceuticals announced that Orkambi has secured regulatory approval from the European Commission to treat CF patients ages six to 11 years.

    By Margaret Patrick
  • uploads///Ana Reco Insys
    Company & Industry Overviews

    What Analysts Recommend for Insys Therapeutics and Peers

    Insys Therapeutics (INSY) is a commercial-stage specialty pharmaceutical company headquartered in Chandler, Arizona.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Collaborations and Developments in 4Q17

    Incyte (INCY) has a well-established distribution network in the United States and sells its products Jakafi and Iclusig in the country through its own network.

    By Mike Benson
  • uploads///Q segment performance
    Company & Industry Overviews

    Exploring Mylan’s Diversified Portfolio of Brands

    Product portfolio Mylan’s (MYL) portfolio of branded products includes Creon, Influvac, Dymista, Dona, Betadine, Saugella, and EpiPen. Mylan has a favorable product mix of generic, brand name, and over-the-counter products catering to different therapeutic areas and sold in multiple geographies. Mylan launched Imatinib tablets in the United States in 2017, strengthening its US oncology portfolio, […]

    By Kenneth Smith
  • uploads///Amitiza performance
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017

    Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.

    By Kenneth Smith
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in November 2017

    In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Nektar’s NKTR-358 Collaboration with Eli Lilly Boosted Revenues

    Nektar Therapeutics (NKTR) recognized $128 million of the $150 million upfront payment from Eli Lilly (LLY) related to the development of investigational drug NKTR-358.

    By Margaret Patrick
  • uploads///Neulasta and Neupogen
    Company & Industry Overviews

    How Did Amgen’s Neulasta and Neupogen Perform in 3Q17?

    In 3Q17, Amgen’s (AMGN) Neulasta generated revenues of around $1.1 billion, a ~6% decline on a year-over-year (or YoY) basis and ~3% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Alnylam Pharmaceuticals and Peers

    On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inclisiran: Long-Term Growth Driver for The Medicines Company?

    According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.

    By Margaret Patrick
  • uploads///A Holdings
    Healthcare

    Taking On Exposure to Innovative Biotechnology Stocks

    The iShares NASDAQ Biotechnology ETF (IBB) offers investors targeted exposure to biotechnology and pharmaceutical stocks listed on the NASDAQ.

    By Peter Barnes
  • uploads///A Fund details
    Healthcare

    Benefitting from IBB’s Lower Expense Ratio

    The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.

    By Peter Barnes
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron in September 2017

    Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals’ Shots-on-Goal Business Model

    Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.

    By Margaret Patrick
  • uploads///Part
    Healthcare

    How Ramsay Health Care Became a Cost Leader

    Ramsay Health Care is a market leader in private healthcare in Australia, treating almost 3 million patients each year.

    By VanEck
  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Celgene in August 2017

    Of the 27 analysts covering Celgene (CELG) in August 2017, 12 analysts recommended a “strong buy,” and ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Vertex Pharma Revenues
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Revenue Trend

    In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Prove Effective in Multiple Diseases

    Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Health Sector Overview: Week of June 5–9, 2017

    In the week ending June 9, 2017, the Health Care Select Sector SPDR Fund (XLV) saw a rise of 0.13%.

    By Margaret Patrick
  • uploads///Strensiq Revenues
    Company & Industry Overviews

    Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.

    By Daniel Collins
  • uploads///Amgen Revenue
    Company & Industry Overviews

    What Could Drive Amgen’s Growth in 2017?

    Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.

    By Daniel Collins
  • uploads///part  table
    Real Insights

    Are Stock Returns during Summer Months That Bad?

    The health care sector (IBB) (VHT) (XBI) has been the most challenged sector since Donald Trump’s presidential campaign.

    By Direxion
  • uploads///Graph
    Miscellaneous

    Failed Healthcare Bill Will Impact the Pharmaceutical Industry

    Due to the failure of the new healthcare bill, major pharmaceutical companies witnessed a fall in their share prices from March 23, 2017, to March 27, 2017.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Why Gilead’s Valuation Is Low Compared to Peers

    On a capital-structure-neutral and excess-cash-adjusted basis, Gilead currently trades at ~3.9x, which is lower than the industry average of ~9.8x.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Biogen Continues Its Dominance in the Multiple Sclerosis Segment

    Despite intense competition from peers such as Novartis (NVS), Teva Pharmaceutical (TEVA), and Sanofi (SNY), Biogen captured ~42% of the MS market share in several major markets.

    By Margaret Patrick
  • uploads///Net debt to Gold Price
    Macroeconomic Analysis

    What Might Prevent a US Recession?

    Independent of policy specifics, there exists a growing chance our newly elected president will likely preside over the next recession. After eight years of expansion, there are signs that the economy has entered the “late cycle” phase. The Fed’s efforts to tighten policy could create a further drag on growth. A recession layered onto the […]

    By VanEck
  • uploads///Net debt to Gold Price
    Macroeconomic Analysis

    What Could Prevent a US Recession?

    Independent of policy specifics, there exists a growing chance our newly elected president will likely preside over the next recession. After eight years of expansion, there are signs that the economy has entered the “late cycle” phase. The Fed’s efforts to tighten policy could create a further drag on growth. A recession layered onto the […]

    By VanEck
  • uploads///Graph
    Company & Industry Overviews

    Kyprolis Is Still a Leading Second-Line Multiple Myeloma Therapy

    Amgen (AMGN) is focused on positioning Kyprolis as a leading multiple myeloma (or MM) therapy for relapsed MM patients.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Tecfidera Continued to Lead in the Oral Multiple Sclerosis Market

    In 3Q16, Biogen’s (BIIB) oral multiple sclerosis (or MS) drug, Tecfidera, managed to increase its global market share to ~15%, a year-over-year (or YoY) rise of about 1 point.

    By Margaret Patrick
  • uploads///pe
    Company & Industry Overviews

    The Factors behind Gilead’s Discounted Valuation

    On September 20, 2016, Gilead Sciences (GILD) was trading at a forward PE (price-to-earnings) multiple of 7.14x, which was at a discount compared to its peers.

    By Jillian Dabney
  • uploads///VALUATION
    Company & Industry Overviews

    Why Is Gilead Sciences Trading at a Cheap Valuation?

    On September 22, Gilead Sciences was trading at a forward PE multiple of about 6.9x. Since the beginning of 2016, it has traded at PE multiples of 6.7x–7.1x.

    By Sarah Collins
  • uploads///PRICE
    Company & Industry Overviews

    Analyzing Gilead Sciences’ Stock Performance

    Gilead Sciences (GILD) was trading at $81.7 as of September 21, 2016. It has a 50-day moving average of $79.4 and a 200-day moving average of $86.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Alder BioPharmaceuticals’s Migraine Therapy Shows Promise

    On March 28, 2016, Alder BioPharmaceuticals (ALDR) announced that its migraine prevention therapy, CGRP inhibitor, ALD403, met both the primary and secondary endpoints in a Phase 2b trial.

    By Margaret Patrick
  • uploads///alzheimer
    Company & Industry Overviews

    Market Cheers FDA’s Fast Tracking of BIIB’s Alzheimer’s Treatment

    The U.S. Food and Drug Administration (or FDA) recently awarded the fast track status to aducanumab following the positive results of Biogen’s pre-clinical research.

    By Sarah Collins
  • uploads///Revlimid
    Company & Industry Overviews

    What Are the Possible Threats to Revlimid?

    With Revlimid and Pomalyst/Imnovid in its portfolio, Celgene (CELG) dominates the multiple myeloma market.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Sales from This Amgen Product Helped the Company’s Q2 Earnings

    Despite tough competition from peers such as Celgene and Johnson & Johnson in 2Q16, Amgen’s Kyprolis witnessed a 24% year-over-year rise in total units sold.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ALNY Reports Positive Results from Patisiran’s Open Label Extension Study

    On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its ongoing Phase 2 open label extension study.

    By Margaret Patrick
  • uploads///ANR
    Earnings Report

    Regeneron: How Much Upward Potential Does It Have?

    Regeneron Pharmaceuticals (REGN) could report its 2Q16 financial and operating results on July 14, 2016. In this series, we’ll see what you can expect from REGN ahead of the release.

    By Jillian Dabney
  • uploads///hemophilia
    Company & Industry Overviews

    The Evolution of Hemophilia Treatment—And What It Means for BioMarin

    BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.

    By Jillian Dabney
  • uploads///Brexit
    Miscellaneous

    Effects of Brexit on Pharmaceuticals and the Biotechnology Industry

    Global big pharmaceutical companies that have major exposure to Europe will be impacted significantly by Brexit. The depreciating euro will impact sales.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Shire’s Shareholders Approve Baxalta Merger: What’s Next?

    Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Tops the Biotechnology ETFs in the Last Week of May

    In the week ending May 27, 2016, the SPDR S&P Biotech ETF (XBI) was the top performer among biotechnology ETFs with a return of 5.1%.

    By Peter Neil
  • uploads///Pipeline
    Earnings Report

    How Does Vertex Plan to Expand Beyond Cystic Fibrosis?

    Vertex is trying to expand its product base beyond cystic fibrosis. It holds molecules in the oncology, respiratory, pain, spinal cord, and influenza spaces.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB’s Large-Cap stocks: What Drove Regeneron’s Positive Results?

    Regeneron Pharmaceuticals (REGN) gained 2.1% and closed at $384.52 on May 2, 2016.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals: Valuation Compared to Its Peers

    In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva

    Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Large-Caps: Mylan Launches Generic Version of Lopressor

    In a press release, Mylan (MYL) announced that it has launched a generic version of Novartis’s Lopressor tablets.

    By Peter Neil
  • uploads///ADHD portfolio
    Company & Industry Overviews

    How Vyvanse Could Fuel Shire’s ADHD Portfolio Sales

    Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.

    By Jillian Dabney
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.